Arabian Journal of Chemistry (Mar 2022)
Ziziphora clinopodioides Lam leaf aqueous extract mediated novel green synthesis of iron nanoparticles and its anti-hemolytic anemia potential: A chemobiological study
Abstract
In this study, the aqueous extract Ziziphora clinopodioides was used to biosynthesis of iron nanoparticles. A green, productive, and environmentally method was developed for the valuable study and the effective preparation of the green-synthesis of iron nanoparticles using aqueous extracts from the leaf of Ziziphora clinopodioides as a result of reducing and stabilizing factor. The simplicity of the synthesis procedures and easy work up are the benefits of the present study. The structural and morphological characterization of green‐synthesized FeNPs was performed by Uv–Vis. and FT-IR spectroscopy, XRD, SEM, and EDX techniques. The SEM images have exhibited an equal and uniform spherical morphology in size of 30.04. We also investigated the anti-hemolytic anemia property of FeNPs in an animal model of hemolytic anemia. In vivo assay, induction of hemolytic anemia was done by phenylhydrazine in mice. FeNPs significantly reduced the weight and volume of liver and spleen and the concentration of pro-inflammatory cytokines and increased the body weight, the anti-inflammatory cytokines concentration, and the total platelet, WBC, neutrophil, lymphocyte, eosinophil, monocyte, and basophil counts, and RBC parameters as compared to the untreated mice. About the biochemical parameters, FeNPs significantly increased GPx, CAT, and SOD in serum, liver, and spleen, and also HDL, total protein, and albumin in serum, and decreased GR in serum, liver, and spleen, and also erythropoietin, ferritin, ferrous, creatinine, urea, LDL, triglyceride, cholesterol, GGT, ALT, AST, and ALP in serum as compared to the anemic mice. DPPH test revealed similar antioxidant potentials for FeNPs and Butylated hydroxytoluene. FeNPs had low cell viability dose-dependently against HUVEC cell line. It appears that FeNPs can be administrated as a hematoprotective and anti-hemolytic anemia drug or supplement for the treatment of hemolytic anemia in the clinical trial.
